

Supplementation of Nigella Sativa as Antioxidant in COVID-19 Patients: *In Silico* Study via the Nrf2-Keap1 Pathway

Q2 Ika Kustiyah¹, Ira Nurrasyidah², Noor Muthmainah³, Holly Diany²,
Noer Komari⁴, Eko Suhartono^{5*}

¹Department of Pathology & Anatomy, Faculty of Medicine, Lambung Mangkurat University, Banjarmasin, Indonesia

²Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Lambung Mangkurat University, Banjarmasin, Indonesia

³Department of Microbiology and Parasitology, Faculty of Medicine, Lambung Mangkurat University, Banjarmasin, Indonesia

⁴Department of Chemistry, Faculty of Mathematics and Natural Sciences, Lambung Mangkurat University, Banjarmasin, Indonesia

⁵Department of Medical Chemistry/Biochemistry, Faculty of Medicine, Lambung Mangkurat University, Banjarmasin, Indonesia

Received: 22nd June, 2022; Revised: 28th August, 2022; Accepted: 1st September, 2022; Available Online: 25th September, 2022

ABSTRACT

The human corona virus disease of 2019 is a viral disease that can produce oxidative stress due to reduced antioxidant activity. Black cumin is a plant that can be taken as a supplement to boost antioxidant levels in the body, although the process is still unknown. As a result, the *in silico* method will be used to screen the potential of Nigella Sativa peptide as an antioxidant in this study. Protein tracking was done using the UniProt database (<https://www.uniprot.org/>), with KEAP1 as the target protein (GDP: 5CGJ). Molecular docking was performed using Patchdock Server and antioxidant activity was determined using <https://services.healthtech.dtu.dk/service.php?AnOxPePred-1.0>. The researchers concluded that peptides found in Nigella Sativa's NAD(P)H-quinone oxidoreductase subunit 5, chloroplastic protein, had antioxidant potential through suppressing KEAP1 activity with the lowest ACE in Tyr-Tyr-Glu and Cys-Tyr-Tyr.

Keywords: COVID-19, KEAP1, Nigella Sativa, Nrf2, Peptide.

International Journal of Drug Delivery Technology (2022); DOI: 10.25258/ijddt.12.3.00

How to cite this article: Kustiyah I., Nurrasyidah I., Muthmainah N., Diany H., Komari N., Suhartono E., Supplementation of Nigella Sativa as Antioxidant in COVID-19 Patients: *In Silico* Study via the Nrf2-Keap1 Pathway. International Journal of Drug Delivery Technology. 2022;12(3):1-3.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Human coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a single-chain RNA virus that has a capsule, nucleocapsid, spike glycoprotein, and other non-structural proteins.^{1,2} There were 4,260,677 confirmed COVID-19 patients in Indonesia between March 2, 2020 and December 20, 2021, with 144,013 deaths.²

COVID-19 infection is caused by viruses that enter cells and increase oxygen consumption, causing hypoxia in the cells, which causes oxidative stress and increased activity of antioxidant enzymes like peroxidase, catalase, and superoxide dismutase. Furthermore, oxidative stress can activate a number of transcription factors, including nuclear factor kappa-B

(NF κ B), p53, HIF-hypoxia-inducible factor 1 α , peroxisome proliferator-activated receptor γ (PPAR- γ), β -catenin/Wnt, and Nrf2.^{3,4}

The erythroid 2-related nuclear factor protein (Nrf2) is a key protein in the Nrf2/KEAP1 pathway, which controls the antioxidant response. Nrf2 binds to the Kelch ECH Associating Protein 1 (KEAP1) protein when it is inactive. Free Nrf2, on the other hand, will translocate into the nucleus of the cell and trigger the expression of antioxidant genes like superoxide dismutase, catalase, and peroxidase.^{3,4}

Figure 1: NAD(P)H-quinone oxidoreductase subunit 5, chloroplastic protein sequence of NS

Q1